WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be well-tolerated Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study
Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to commercialization SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™) planned for the second quarter of 2026 Initiation of Phase 1 study of TSC-102-A01 and TSC-102-A03 targeting CD45 in patients with
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an